利妥昔单抗联合甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的临床疗效

[Clinical Therapeutic Efficacy of Rituximab Combined with Methotrexate on Primary Central Nervous System Lymphoma].

作者信息

Luo Wei, Ji Lin-Hua, Geng Hui, Ma Xiao-Jing, Xiong Hua, Yin Qi-Chao, Yin Yu-Juan, Yu Lin, Ma Jie

机构信息

Department of Hematology, Qinghai University Affiliated Hospital, Xining 810001, Qinghai Province, China. E-mail:

Department of Hematology, Qinghai University Affiliated Hospital, Xining 810001, Qinghai Province, China.

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Apr;24(2):444-7. doi: 10.7534/j.issn.1009-2137.2016.02.025.

DOI:10.7534/j.issn.1009-2137.2016.02.025

PMID:27151007

Abstract

OBJECTIVE

To investigate the therapeutic efficacy of rituximab combined with methotrexate on patients with primary central nervous system lymphoma.

METHODS

Fifty eight patients with central nervous system lymphoma treated in our hospital from February 2008 to September 2011 years were randomly divided into the observation group and the control group. The control group was treated with methotrexate combined with whole brain radiotherapy; the observation group was treated by rituximab combined with methotrexate. The curative efficacy, adverse effects, life quality, and the 1 and 3 year survival rate after 2 cycles of treatment were compared between 2 groups.

RESULTS

The total effective rate of observation group was 82.76%, which significantly higher than 58.62% of the control group (P < 0.05). In observation group, the incidences of anemia, liver damage, gastrointestinal side effect and oral ulcer were significantly lower than that in control group, respectively (P < 0.05). The physiological function, physical function, health status, social and emotional function in the observation group were significantly higher than those in the control group (P < 0.05), 1 and 3 years survival rates in the observation group were 86.21% and 62.07%, significantly higher than 58.62% and 31.03% in the control group (P < 0.05).

CONCLUSION

Targeted therapy combined with chemotherapy for the primary central nervous system lymphoma can improve the patients' outcomes, reduce adverse effects, and improve the quality of life and survival rate.

摘要

目的

探讨利妥昔单抗联合甲氨蝶呤治疗原发性中枢神经系统淋巴瘤患者的疗效。

方法

选取2008年2月至2011年9月在我院治疗的58例中枢神经系统淋巴瘤患者，随机分为观察组和对照组。对照组采用甲氨蝶呤联合全脑放疗治疗；观察组采用利妥昔单抗联合甲氨蝶呤治疗。比较两组患者治疗2个周期后的疗效、不良反应、生活质量及1年和3年生存率。

结果

观察组总有效率为82.76%，显著高于对照组的58.62%（P<0.05）。观察组贫血、肝损害、胃肠道副作用及口腔溃疡的发生率分别显著低于对照组（P<0.05）。观察组的生理功能、躯体功能、健康状况、社会及情感功能显著高于对照组（P<0.05），观察组1年和3年生存率分别为86.21%和62.07%，显著高于对照组的58.62%和31.03%（P<0.05）。